Company news

Disc Medicine, Inc. news in 2026

Disc Medicine, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

November 5, 2026

Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

November 4, 2026

Disc Medicine to Participate in Upcoming Investor Conferences

November 2, 2026

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

October 20, 2026

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

October 19, 2026

Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

October 19, 2026

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

October 18, 2026

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

August 31, 2026

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

July 29, 2026

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

June 11, 2026

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

June 8, 2026

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis and Anemia at the 2026 American Society of Clinical Oncology Annual Meeting

June 3, 2026

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2026

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2026

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

June 1, 2026

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

May 12, 2026

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 20, 2026

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

March 25, 2026

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

Bitopertin Regulatory Update

February 17, 2026

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

February 13, 2026

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

January 12, 2026

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

January 12, 2026

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Decks in 2026